Background: Treatment strategies for patients with non-small cell lung cancer (NSCLC) depend on various factors including physical condition, complications, tumor histology, and molecular profiling. Even if initial chemotherapy is efficacious, almost all patients develop treatment resistance. Invasive rebiopsy from sites of recurrence might provide insight into resistance mechanisms and aid in
Introduction
Although lung cancer remains the leading cause of death among all cancers, 1,2 progress in treatment has been remarkable in the past several decades because of molecular-targeted drugs, such as those used for epidermal growth factor receptor (EGFR)-positive and anaplastic lymphoma kinase (ALK)-positive tumors. Furthermore, immune-checkpoint inhibitors, including those targeting programmed cell death 1 and programmed death-ligand 1, have been developed for non-small cell lung cancer (NSCLC), with several chemotherapeutics already approved and in use. Therefore, sequential treatment strategies using chemotherapeutic agents among the several available classes should be considered in individual patients.
Almost all advanced or metastatic lung cancers progress after initial chemotherapy. In these cases, invasive rebiopsy should be considered for selecting appropriate sequential chemotherapy, given that tissue resampling can provide insight into the resistance mechanisms underlying chemotherapy, especially molecular-targeted drugs. 3, 4 A recent study suggested that the most important factor for successful treatment of these patients was adequate tissue resampling to ensure the detection of novel mutations during disease progression. 5 For example, 50-60% of patients with mutations in EGFR conferring sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), such as deletions in exon 19 and a point mutation substituting L858R in exon 21, treated with first-generation or second-generation EGFR-TKIs (gefitinib, erlotinib, and afatinib) were found to later acquire a second mutation in EGFR (T790M), which led to resistance; 6-9 a third-generation EGFR-TKI, osimertinib, has been developed to overcome this resistance. 3, 10 Appropriate treatment for NSCLC patients is determined with consideration of their physical condition, complications, histological type, pathological findings including immunostaining, and tumor mutation status. For diagnosis and molecular characterization of lung tumors, 11, 12 adequate invasive tissue-sampling procedures, such as bronchoscopy, endobronchial ultrasound, computed tomography-guided biopsy, and even surgical biopsy, are necessary, all of which are associated with pain. In clinical practice, invasive rebiopsy is an essential approach for selection of the next chemotherapy, which, however, is limited by tissue availability [13] [14] [15] [16] [17] [18] and patient burden related to the initial biopsy.
This study investigated patient awareness of invasive rebiopsy in advanced NSCLC, with the goal of determining factors that will improve the rate of this invasive procedure necessary for optimal treatment.
Methods

Study patients
This prospective study recruited patients with locally advanced or metastatic NSCLC under protocol approved by the Kitasato University Medical Ethics Organization (B15-31). Eligible patients were those with a pathological diagnosis of NSCLC and who had a planned first-line or second-line chemotherapy at Kitasato University Hospital in Kanagawa, Japan, between July 2015 and May 2016. We received written consent from each patient in this study. The third-generation EGFR-TKI, osimertinib, had not been approved in Japan at the time this study was carried out. After obtaining written consent, patient awareness was evaluated with a survey, and patient characteristics and clinical data were collected.
At diagnosis, invasive procedures including flexible bronchoscopy, computed tomography-guided percutaneous lung biopsy, open lung biopsy, cytopathological examination of pleural or pericardial fluid, transesophageal needle aspiration, or brain tumor resection were performed with or without conscious sedation, after appropriate informed consent was obtained (Table 1) . After the diagnosis, a questionnaire was carried out using multiple selectable questionnaires (Table 2) at two time points: before starting first-line chemotherapy (cohort 1), and at disease ‡Including two brain tumor resections and one transesophageal needle aspiration. Ad, adenocarcinoma; Chemo, chemotherapy; CRT, chemoradiotherapy; NOS, not otherwise specified; Sq, squamous cell carcinoma. 
Statistical analysis
The impact of clinical factors on patients' decision on invasive rebiopsy was assessed using Pearson's κ 2 test. All analyses were performed using SPSS statistical software (SPSS, Chicago, IL, USA).
Results
Patient characteristics
We enrolled two cohorts of patients depending on when we asked them about tissue rebiopsy: 50 patients who were asked before first-line chemotherapy about rebiopsy if their disease progressed after initial chemotherapy (cohort 1), and 30 patients who were asked at the time of disease progression after initial chemotherapy and when second-line chemotherapy was being planned (cohort 2; Fig 1) 
Aggregate results of the survey
In cohort 1, 37 (74%) of the 50 patients eventually provided consent for rebiopsy, whereas 13 patients (26%) rejected rebiopsy (Fig 2a) . In cohort 2, 18 (60%) of the 30 patients eventually provided consent for rebiopsy, whereas 10 patients (33%) rejected rebiopsy (Fig 2b) . Reasons for the responses to the invasive rebiopsy option are shown in Figure 3 . Briefly, 36 (97%) of the 37 patients in cohort 1 and 17 (100%) of the 17 patients in cohort 2 who accepted the rebiopsy (groups 1 and 2 in Fig 3a) followed their doctor's recommendation to select optimal treatment because of tissue sampling. Conversely, the reasons for refusal of invasive rebiopsy were according to painful experience of an initial biopsy (100% and 80% in cohorts 1 and 2, respectively) and apprehension because of poor physical condition (38% and 40% in cohorts 1 and 2, respectively; Fig 3b) . Furthermore, five (38%) of the 13 patients in cohort 1, and four (40%) of the 10 patients in cohort 2 who rejected the rebiopsy stated that they would consider non-invasive examination if it were an option.
There were no associations between clinical factors and consent rate of invasive rebiopsy (Tables 3, S1 ). In this study, the number of biopsies performed before the survey were once (n = 71) or twice (n = 9) for confirmed diagnosis of lung cancer, and it was not associated with the patients' will to agree to tissue rebiopsy (P = 0.60). Although median durations from prior biopsy to the In cohort 2, on the relationship between the initial treatment effects and decision of rebiopsy, five (42%) of 12 patients who had partial response, 10 (83%) of 12 patients who had stable disease, and three (50%) of six patients who had disease progression agreed to invasive rebiopsy. During the study, seven (14%) of the 50 patients in cohort 1 had disease progression after initial chemotherapy and were included in cohort 2 as a survey respondent (Fig 1) . Two (40%) of the five patients who accepted rebiopsy later changed their decision and refused invasive rebiopsy.
This study was carried out before approval of osimertinib, which requires rebiopsy to prove EGFR T790M mutation, and invasive rebiopsy was not performed before carrying out the questionnaire survey. After approval of osimertinib and PD-L1 immunostaining, 16 (32%) of 50 patients in cohort 1, and 10 (30%) of 30 patients in cohort 2 underwent invasive rebiopsy in the course of treatment. Among the 22 of 73 patients in cohort 1 and 2 who received invasive tissue-rebiopsy, which excluded pleural lavage cytology, 11 (45%) patients had rejected the questionnaire survey carried out in advance.
Discussion
With continuing advances in the treatment of advanced NSCLC, development of molecular-targeted drugs 19 and clinical indications of immune-checkpoint inhibitors [20] [21] [22] require treatment strategies on the basis of molecular profiling of tumors. Furthermore, elucidation of the resistance mechanisms can lead to new therapeutic strategies, 3, 23, 24 which are best illustrated by the discovery of the EGFR Reasons for the decision on invasive rebiopsy based on the study survey (see Table 2 ). T790M mutation found after the implementation of firstgeneration and second-generation EGFR-TKIs, and approval of the third-generation EGFR-TKI, osimertinib.
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Rebiopsy is a feasible approach with a reported technical success rate of approximately 80% in advanced NSCLC patients without severe complications. [15] [16] [17] 25 Although reassessment of tumor at recurrence is also necessary in clinical practice, invasive rebiopsy is accompanied by pain. In this study, poor physical condition (option 6) and the difficulty of the test (option 7) were most of the reasons for refusal. Three of five patients who chose the option 6 were PS 2 or 3, and the remaining two had chosen the options 6 and 7 at the same time as reason for refusal. The option 7 indicated the difficulty of the invasive examination itself, especially bronchoscopy, which accounted for 86% in this study, was highly painful in patients. Strategies to improve the rate of agreement for rebiopsy should consider both the availability of lesions for rebiopsy and patient consent. We found that this painful procedure, which was accepted by approximately 60-70% of the patients as part of their own treatment strategy, was rejected by 30-40% of the patients; in addition, the rejection rate might increase with worsening disease. Our data suggested that explanation of rebiopsy as a potential therapeutic strategy to the patient during the early treatment phase might be important.
Although the standard genotyping approach includes invasive tissue biopsy, its clinical utility is limited by a lack of available tissue, potential complications, and patient discomfort. 26 Liquid biopsies, such as those evaluating circulating tumor DNA or RNA, circulating tumor cells, and exosomes, are potentially useful for the analysis of tumor cell genetics using blood samples in patients with malignancies, and these approaches have been increasingly translated from research to clinical practice. [27] [28] [29] [30] For example, EGFR mutation testing using blood samples in advanced NSCLC patients is feasible and can be utilized in patient selection for targeted therapy in conditions where tissue testing cannot be achieved. 25, [31] [32] [33] [34] In the current study, approximately half of the patients expected the development of non-invasive approaches, although bloodbased testing is considered to complement tissue biopsy. 35, 36 Non-invasive liquid biopsy, which does not add burden on patients, should be validated as an alternative approach to evaluate tumor products comprehensively.
The current study has several limitations. First, this was a patient awareness survey from a single institution and the sample size was small; thus, the results cannot be regarded as definitive. However, there are no comprehensive reports on patient awareness of invasive rebiopsy, and the current data should be useful in the clinical setting. Second, patient background characteristics varied in the current study. In EGFR-mutant patients, the selection of therapeutic agents depends on the secondary mutation status in the resistant tumor; therefore, the significance of invasive rebiopsy is high. However, the current study was performed before osimertinib approval in Japan. Our data suggested that the rate of consent was not associated with patient background characteristics, which should aid clinicians in reassessment of recurrent tumors that might become increasingly necessary in patients with EGFR mutations and those with relapsed disease, because of the advances in molecular target therapy and immunotherapy. Finally, bronchoscopy is carried out with light sedation for local anesthesia at the study hospital, which might lead to experience of pain during the initial examination. Therefore, the impression of the initial examination might have contributed to the results of the survey.
Invasive rebiopsy at the time of recurrence has become increasingly important for treatment selection and therapeutic development in patients with advanced NSCLC. However, the findings of the current study were that the 20-30% of patients with advanced NSCLC experienced great pain; therefore, treatment strategies including rebiopsy as a potential approach for suitable tissue sampling should be discussed with patients during the early treatment phase. Furthermore, it is necessary to focus on the development and evaluation of non-invasive tests, such as liquid biopsy, that cause less pain and burden for patients. We believe that the findings of the current study will aid clinicians by highlighting the need for less invasive methods to detect biomarkers and the importance of providing better information on rebiopsy probability to patients.
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